Literature DB >> 18348878

Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment.

Gisèle Soubrane1.   

Abstract

Choroidal neovascularization is a common cause of vision loss in patients with pathologic myopia, often resulting in irreversible central vision loss. This is particularly important because choroidal neovascularization secondary to pathologic myopia affects many people of working age. Patients may be limited in the types of tasks they can perform effectively or may even have to give up work; thus, in addition to the emotional strain, the vision loss caused by choroidal neovascularization can have a severe impact on career expectations and financial status. This is an important issue for younger patients who may be supporting themselves and their families. In this article, the epidemiology and risk factors of pathologic myopia are reviewed, as well as the pathologic mechanisms, clinical features, and diagnostic tests for choroidal neovascularization secondary to pathologic myopia. The focus of the article is on treatment options, which until recently were limited. The evidence for the beneficial effects of laser photocoagulation, photodynamic therapy with verteporfin, surgery, and other techniques in the treatment of choroidal neovascularization secondary to pathologic myopia will be evaluated.

Entities:  

Mesh:

Year:  2008        PMID: 18348878     DOI: 10.1016/j.survophthal.2007.12.004

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  29 in total

1.  Effect of pathological myopia on biomechanical properties: a study by ocular response analyzer.

Authors:  Veysi Öner; Mehmet Taş; Erdal Özkaya; Yavuz Oruç
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

2.  A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Authors:  Alfredo Pece; Paolo Milani; Carla Monteleone; Costantino John Trombetta; Giuseppe De Crecchio; Giuseppe Fasolino; Domenica Matranga; Salvatore Cillino; Maria Vadalà
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-13       Impact factor: 3.117

3.  [Morphological features of myopic choroidal neovascularization: differences to neovascular age-related macular degeneration].

Authors:  W Inhoffen; F Ziemssen
Journal:  Ophthalmologe       Date:  2012-08       Impact factor: 1.059

4.  [Statement of the Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society), the Retinologische Gesellschaft (German Retina Society) and the Berufsverband der Augenärzte Deutschlands (German Professional Association of Ophthalmologists) on the therapy of choroidal neovascularization in myopia. State: March 2014].

Authors:  D Pauleikhoff; B Bertram; D Claessens
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

5.  Intravitreal aflibercept for myopic choroidal neovascularization.

Authors:  Alfredo Pece; Paolo Milani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-11       Impact factor: 3.117

Review 6.  Gene profiling in experimental models of eye growth: clues to myopia pathogenesis.

Authors:  Richard A Stone; Tejvir S Khurana
Journal:  Vision Res       Date:  2010-04-02       Impact factor: 1.886

Review 7.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

8.  Diagnosis and treatment of myopic traction maculopathy.

Authors:  Ping-Bo Ouyang; Xuan-Chu Duan; Xiao-Hua Zhu
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

9.  Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF.

Authors:  Stephen J Kim; Hassanain S Toma; Joshua M Barnett; John S Penn
Journal:  Exp Eye Res       Date:  2010-07-24       Impact factor: 3.467

10.  Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.

Authors:  A Tufail; P J Patel; S Sivaprasad; W Amoaku; A C Browning; M Cole; R Gale; S George; A J Lotery; M Majid; M McKibbin; G Menon; Y Yang; C Andrews; C Brittain; A Osborne
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.